Tarsus Pharmaceuticals (TARS) Projected to Post Earnings on Wednesday

Key Points

• Tarsus Pharmaceuticals is expected to report Q2 2025 earnings on August 6, with analysts predicting a loss of ($0.41) per share and revenue of $95.81 million.
• The company's stock has declined by 3.0%, trading at $38.82, with a market cap of $1.63 billion and a negative P/E ratio of -14.22.
• Multiple analysts have rated Tarsus Pharmaceuticals as a "Moderate Buy," with a consensus target price of $66.67, suggesting optimism about the company's prospects.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($0.41) per share and revenue of $95.81 million for the quarter.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million during the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. On average, analysts expect Tarsus Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Down 3.0%

Shares of NASDAQ:TARS traded down $1.18 during trading on Thursday, reaching $38.82. 622,387 shares of the company traded hands, compared to its average volume of 652,012. The firm has a fifty day simple moving average of $41.53 and a 200 day simple moving average of $45.87. The firm has a market cap of $1.63 billion, a P/E ratio of -14.22 and a beta of 0.80. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Large investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its holdings in Tarsus Pharmaceuticals by 105.8% in the first quarter. Jane Street Group LLC now owns 10,456 shares of the company's stock valued at $537,000 after buying an additional 190,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company's stock valued at $1,137,000 after purchasing an additional 1,217 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company's stock valued at $3,659,000 after purchasing an additional 1,394 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TARS shares. Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price objective for the company. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research report on Tuesday, May 27th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.